These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16827619)

  • 1. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Jun; 5(3):347-63. PubMed ID: 16827619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
    LaCasse RA; Follis KE; Trahey M; Scarborough JD; Littman DR; Nunberg JH
    Science; 1999 Jan; 283(5400):357-62. PubMed ID: 9888845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
    Wyatt R; Sodroski J
    Science; 1998 Jun; 280(5371):1884-8. PubMed ID: 9632381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
    Montefiori DC; Evans TG
    AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
    [No Abstract]   [Full Text] [Related]  

  • 9. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.
    Ringe RP; Colin P; Torres JL; Yasmeen A; Lee WH; Cupo A; Ward AB; Klasse PJ; Moore JP
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.
    Khayat R; Lee JH; Julien JP; Cupo A; Klasse PJ; Sanders RW; Moore JP; Wilson IA; Ward AB
    J Virol; 2013 Sep; 87(17):9865-72. PubMed ID: 23824817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies to HIV-1 induced by immunization.
    McCoy LE; Weiss RA
    J Exp Med; 2013 Feb; 210(2):209-23. PubMed ID: 23401570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.
    Parren PW; Gauduin MC; Koup RA; Poignard P; Fisicaro P; Burton DR; Sattentau QJ
    Immunol Lett; 1997 Jun; 57(1-3):105-12. PubMed ID: 9232434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in the rational design of an AIDS vaccine.
    Nabel GJ; Kwong PD; Mascola JR
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.